<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583098</url>
  </required_header>
  <id_info>
    <org_study_id>2020-08-006</org_study_id>
    <nct_id>NCT04583098</nct_id>
  </id_info>
  <brief_title>The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms</brief_title>
  <official_title>The Effect of Fecal Microbiota Transplantation on the Decolonization of Carbapenem-resistant Enterobacteriaceae or Vancomycin-resistant Enterococci in the Gut</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chuncheon Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chuncheon Sacred Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of fecal microbiota transplantation for the&#xD;
      decolonization of carbapenem-resistant Enterobacteriaceae or vancomycin-resistant Enterococci&#xD;
      in the gut.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>successful decolonization of carbapenem-resistant Enterobacteriaceae or vancomycin-resistant Enterococci in the gut within 3 months after fecal microbiota transplantation</measure>
    <time_frame>within 3 months</time_frame>
    <description>Successful decolonization of carbapenem-resistant Enterobacteriaceae or vancomycin-resistant Enterococci was defined as three consecutive, carbapenem-resistant Enterobacteriaceae or vancomycin-resistant Enterococci-negative surveillance rectal swab cultures repeated with a 3-day interval within 3 months after fecal microbiota transplantation</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Carbapenem-Resistant Enterobacteriaceae Infection</condition>
  <condition>Vancomycin-Resistant Enterococcal Infection</condition>
  <arm_group>
    <arm_group_label>carbapenem-resistant Enterobacteriaceae</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>vancomycin-resistant Enterococci</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fecal microbiota transplantation</intervention_name>
    <description>frozen stool from donors who had already finished recommended blood &amp; stool screening for stool donors</description>
    <arm_group_label>carbapenem-resistant Enterobacteriaceae</arm_group_label>
    <arm_group_label>vancomycin-resistant Enterococci</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      stool (gut microbiota)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CRE- or VRE-rectal colonizer who have given written informed consent for fecal microbiota&#xD;
        transplantation and collection of stool samples for CRE or VRE decolonization&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 19 years-old with carbapenem-resistant Enterobacteriaceae(CRE) or&#xD;
             vancomycin-resistant Enterococci(VRE) rectal colonization&#xD;
&#xD;
          -  Patients who have received written informed consent for fecal microbiota&#xD;
             transplantation and collection of stool samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have not completed acute-phase treatment, including antibiotic treatment&#xD;
&#xD;
          -  If patients are pregnant, may be pregnant, or are lactating&#xD;
&#xD;
          -  Patients who have not received written informed consent for the study enrollment&#xD;
&#xD;
          -  Patients who are judged to be unhelpful to participate in the study according to the&#xD;
             researcher's judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung Soon Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chuncheon Sacred Heart Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung Soon Lee, MD</last_name>
    <phone>+82-33-240-5599</phone>
    <email>hushh93@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ki Tae Suk, MD, PhD</last_name>
    <phone>+82332405826</phone>
    <email>ktsuk@hallym.or.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon-do</state>
        <zip>24253</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Soon Lee, MD</last_name>
      <phone>+82-33-240-5599</phone>
      <email>hushh93@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ki Tae Suk, MD, PhD</last_name>
      <phone>+82-33-240-5826</phone>
      <email>ktsuk@hallym.or.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 4, 2020</last_update_submitted>
  <last_update_submitted_qc>October 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Carbapenem-Resistant Enterobacteriaceae</keyword>
  <keyword>Vancomycin-Resistant Enterococci</keyword>
  <keyword>Gastrointestinal Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

